Core Scientific, Inc./tx
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
7 — Warrant Liabilities
- WARRANT LIABILITIES
Warrant Agreement
On January 23, 2024, the Company entered into a warrant agreement (the “Warrant Agreement”) providing for the issuance of 98,313,313 warrants, each exercisable forone share of New Common Stock at an exercise price of $6.81 per share (the “Tranche 1 Warrants”), and 81,927,898 warrants, each exercisable forone share of New Common Stock at an exercise price of $0.01 per share (the “Tranche 2 Warrants” and, together with the Tranche 1 Warrants, the “Warrants”). The Tranche 1 Warrants expire on January 23, 2027, and the Tranche 2 Warrants expire on January 23, 2029.
During the three and six months ended June 30, 2025,0.1 million and 0.1 million Tranche 1 Warrants were exercised, respectively, which resulted in cash receipts of $0.3 million and $0.6 million. As of June 30, 2025, there were 97.5 million unexercised Tranche 1 Warrants.
During the three and six months ended June 30, 2025,2.5 million and 5.9 million Tranche 2 Warrants were exercised, respectively, which resulted in immaterial cash receipts. As of June 30, 2025, there were 15.1 million unexercised Tranche 2 Warrants.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.